Thymosin-β4 inhibits proliferation and induces apoptosis of hepatic stellate cells through PI3K/AKT pathway
Metrics: PDF 588 views | HTML 1077 views | ?
Lili Zhu1,2, Mingliang Cheng1, Yongmei Liu1, Yumei Yao1, Zixin Zhu3, Baofang Zhang1, Qiuju Mou2 and Yiju Cheng1
1Department of Infectious Diseases, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
2The Affliated Baiyun Hospital of Guizhou Medical University, Guiyang, Guizhou, China
3Guizhou Medical University, Guiyang, Guizhou, China
Mingliang Cheng, email: email@example.com
Keywords: Thymosin-β4, liver fibrosis, hepatic stellate cell, AKT
Received: April 14, 2017 Accepted: May 09, 2017 Published: June 28, 2017
Liver fibrosis is a necessary stage for chronic liver diseases, and serious threat to human health. Hepatic fibrosis is a necessary stage for chronic liver diseases. Hepatic stellate cells (HSCs) are the primary cell type responsible for fibrosis. Thymosin beta 4 (Tβ4) has a potential role in the pathogenesis of liver fibrosis and that it is especially associated with the activation of HSCs, however, the underlying mechanisms are not fully elucidated. Herein, we investigated the potential role of Tβ4 in liver fibrosis by describing the effects of Tβ4, and we discuss the possible signaling pathway regulated by Tβ4. The expression of Tβ4 was significantly decreased in human HSC cell line LX-2 and CCl4-treated mouse liver. The depletion of Tβ4 significantly associated with the activation of HSCs via the enhanced expression of α-SMA and vimentin. Tβ4 significantly suppressed the viability and migration of HSCs. Understanding the potential effects and regulatory mechanism of Tβ4 in liver fibrosis might help to provide a novel treatment for patients with liver fibrosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.